LRRK2

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, History of the University of Maryland, College Park, Safety, Therapy, Computational chemistry, University, LRRK2, Psoriasis, Mathematics, IND, Acquisition, Drug discovery, Research, Engineering, Outline of physical science, Neurology, Patient, KPI-driven code analysis, CNS, College Park, Polymer, MALT1, Faculty, Materials science, Lymphoid leukemia, AbbVie, Machine learning, Biochemistry, TYK2, Biophysics, Bristol Myers Squibb, Hair, CDC7, Society, Pharmacokinetics, Pharmaceutical industry, Nimbus, IPO

NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis.

Key Points: 
  • NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis.
  • The distribution was on account of Schrödinger’s equity stake in Nimbus, which as of December 31, 2022, was 3.8% on a fully diluted basis.
  • Schrödinger participated in the IPO and now holds a 3.7 percent equity stake in Structure Therapeutics.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, at 4:30 p.m.

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, February 27, 2023
Hearing, Asos, IND, Lupus, Biomarker, PTV, Biology, Therapy, Neuroinflammation, ETV, Multiple sclerosis, Hunter syndrome, ALS, Safety, MS, TREM2, Takeda, Standard of care, DSM-IV codes, Patient, ATV, SGSH, IDS, CLE, Hospital, ISR, Parkinson's disease, COMPASS, RIPK1, LRRK2, Type 3 submergence transport vehicle, MPS II, CSF, Brain, Massachusetts General Hospital, Bank, BBB, CNS, MGH, Glycogen storage disease, MPS, The Annual, International Symposium on Endovascular Therapy, Traffic barrier, Sanfilippo syndrome, Bank of America, Sanfilippo, N-sulfoglucosamine sulfohydrolase, LUMA, ASO, SAN, Conference, Hunting, OTV, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Fine chemical, Cryptocurrency, Biogen, Sanofi

In February 2023, at the WORLDSymposiumTM, Denali reported additional interim data from the open-label, single-arm Phase 1/2 study of DNL310.

Key Points: 
  • In February 2023, at the WORLDSymposiumTM, Denali reported additional interim data from the open-label, single-arm Phase 1/2 study of DNL310.
  • The Phase 2/3 COMPASS study continues to enroll up to 54 participants with MPS II with and without neuronopathic disease.
  • In October 2022, Denali raised net proceeds of approximately $296.2 million through a public offering of its common stock.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were $1.34 billion as of December 31, 2022.

CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics

Retrieved on: 
Monday, January 9, 2023
Disease, Neurodegeneration, Safety, PD, Genetics, Biogen, Partnership, Patient, Diagnosis, Therapy, Drug discovery, HIV disease progression rates, ClinicalTrials.gov, Denali, Pharmaceutical industry, LRRK2

In 2018, CENTOGENE entered a strategic collaboration with Denali Therapeutics for the targeted global identification of PD patients with genetic variations in the LRRK2 gene.

Key Points: 
  • In 2018, CENTOGENE entered a strategic collaboration with Denali Therapeutics for the targeted global identification of PD patients with genetic variations in the LRRK2 gene.
  • CENTOGENE conducts clinical studies with pharma partners around the world, such as Denali Therapeutics.
  • “Parkinson’s disease is a devastating neurodegenerative disease – affecting over 10 million people worldwide from all walks of life.
  • There is an urgent medical need to unveil multidimensional data,” said Kim Stratton, Chief Executive Officer at CENTOGENE.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Research, Technology, Neurology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, IND, Type 2, Hart–Scott–Rodino Antitrust Improvements Act, Publication, Therapy, CNS, TYK2, LRRK2, Strategic planning, FDA, Pancreatic serous cystadenoma, Psoriasis, Neurology, Astex, MALT1, Ulcerative colitis, ASH, Manuscript, CDC7, Drug discovery, Takeda, Patient, Drug design, Webcast, Software, Ajax, MBBS, Blog, Society, UC, Bristol Myers Squibb, Annual general meeting, Ōtsuka, Pharmaceutical industry, Nimbus

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.
  • Schrödinger reported a new program targeting LRRK2, a genetically validated target with therapeutic potential for the treatment of Parkinson’s disease.
  • In 2022, Schrödinger generated cryo-electron microscopy structures of LRRK2 which is helping to accelerate the identification of novel LRRK2 inhibitors.
  • Today Schrödinger outlined the following strategic priorities for 2023:
    Schrödinger will report its fourth quarter and full-year financial results and provide 2023 financial guidance on Tuesday, February 28, 2023, after the financial markets close.

U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is expected to grow with a CAGR of 13.09% and reach $29.28 billion by 2032

Retrieved on: 
Monday, November 28, 2022
Software, Growth, LabCorp, Parkinson's disease, Partnership, LRRK2, Epidemiology, Illumina, Inc., Genetic testing, Research, Ascension, Benchmarking, Drug discovery, Qiagen, Vaccine, Medical imaging, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/us-hereditary-genetic-testing-m...

Key Points: 
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • Competitive Strategy: The report provides insight into the existing competition in the U.S. hereditary genetic testing market.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Kalorama Information: 20 Companies That Have Worked Out Molecular Diagnostic Deals Recently

Retrieved on: 
Thursday, November 17, 2022
Knowledge, Medicine, Bio-Rad Laboratories, Knowledge-centered support, Biotechnology, Partnership, Single-cell analysis, Software, Consortium, Roche, Genomics, AstraZeneca, LRRK2, NGS, IVD, Exact sciences, Patient, Parkinson's disease, Biosensor, Curiosity, SD, Brain, Architecture, Medical device, Medical imaging, Pharmaceutical industry, Antibiotics, Science, Ultima, Meridian, Pirch (company)

ARLINGTON, Va., Nov. 17, 2022 /PRNewswire-PRWeb/ -- According to Kalorama Information's The World Market for Molecular Diagnostics Tests, 11th Edition, the demand for molecular in vitro diagnostics (IVD) means that very often a single firm cannot go it alone and must find partners.

Key Points: 
  • The demand for molecular in vitro diagnostics (IVD) means that often a single firm cannot go it alone and must find partners.
  • Here are 10 key recent deals in the market.
  • Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals.
  • Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology.

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
LRRK2, Investor, Traffic barrier, Stimulator of interferon genes, Adult, Research, Sale, Therapy, Policy, Company, Conference, Food, DYRK1A, APA, Atopic dermatitis, TTK, Compliance, U.S. Securities and Exchange Commission, Time, Pharmacokinetics, Autoimmunity, Inflammation, Patient, Acquisition, COVID-19, Leadership, CLK, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Coronavirus Scientific Advisory Board (Turkey), Down syndrome, Next, AD, Track, TSA, EDT, NDA, SAB, FDA, GLOBE, Intellectual property, Feedback, File, Private Securities Litigation Reform Act, MAD, DRS, SAD, Safety, Part, Part Two, Tyrosine kinase inhibitor, Insurance, Pharmaceutical industry, Vaccine, Security (finance), Video game, Fresh

BOULDER, Colo., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • To better align with our new strategic vision and plans, we recently rebranded the Company to Fresh Tracks Therapeutics, commented Robert Brown, Chief Executive Officer of Fresh Tracks.
  • In the second quarter of 2022, Fresh Tracks entered into an asset purchase agreement (APA) with Botanix SB Inc. (Botanix).
  • Fresh Tracks management will host a conference call today at 4:30 p.m. EDT to discuss the financial results and recent corporate developments.
  • Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.